These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30787627)

  • 21. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
    Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canagliflozin: metabolic, cardiovascular and renal protection.
    Barrios V; Escobar C
    Future Cardiol; 2021 May; 17(3):443-458. PubMed ID: 33538620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
    Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
    Arnott C; Huang Y; Neuen BL; Di Tanna GL; Cannon CP; Oh R; Edwards R; Kavalam M; Rosenthal N; Perkovic V; Jardine MJ; Mahaffey K; Neal B
    Diabetes Obes Metab; 2020 Oct; 22(10):1753-1766. PubMed ID: 32436638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
    Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V
    Clin Kidney J; 2021 May; 14(5):1396-1402. PubMed ID: 34221371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal effects of canagliflozin in type 2 diabetes mellitus.
    Perkovic V; Jardine M; Vijapurkar U; Meininger G
    Curr Med Res Opin; 2015 Dec; 31(12):2219-31. PubMed ID: 26494163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
    Prasanna Kumar KM; Ghosh S; Canovatchel W; Garodia N; Rajashekar S
    Indian J Endocrinol Metab; 2017; 21(1):196-209. PubMed ID: 28217522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial.
    Barraclough JY; Yu J; Figtree GA; Perkovic V; Heerspink HJL; Neuen BL; Cannon CP; Mahaffey KW; Schutte AE; Neal B; Arnott C
    Diabetes Obes Metab; 2022 Jun; 24(6):1072-1083. PubMed ID: 35166429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Canagliflozin (Invokana): kidney SGLT2 cotransporter inhibitor for treating type 2 diabetes].
    Scheen AJ
    Rev Med Liege; 2014 Dec; 69(12):692-9. PubMed ID: 25796788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.
    Satoh H
    Diabetol Int; 2018 Oct; 9(4):212-214. PubMed ID: 30603370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDENCE Trial Data.
    Willis M; Asseburg C; Slee A; Nilsson A; Neslusan C
    Diabetes Ther; 2020 Nov; 11(11):2657-2676. PubMed ID: 32930969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.
    Rastogi A; Bhansali A
    Diabetes Ther; 2017 Dec; 8(6):1245-1251. PubMed ID: 29076040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Rosenthal N; Meininger G; Ways K; Polidori D; Desai M; Qiu R; Alba M; Vercruysse F; Balis D; Shaw W; Edwards R; Bull S; Di Prospero N; Sha S; Rothenberg P; Canovatchel W; Demarest K
    Ann N Y Acad Sci; 2015 Nov; 1358():28-43. PubMed ID: 26305874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis.
    Sinha B; Ghosal S
    Curr Diabetes Rev; 2020; 16(5):509-514. PubMed ID: 31652114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Weiss R; Rosenstock J; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B
    Diabetes Ther; 2015 Sep; 6(3):289-302. PubMed ID: 26081793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
    Mahaffey KW; Jardine MJ; Bompoint S; Cannon CP; Neal B; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Capuano G; de Zeeuw D; Greene T; Levin A; Pollock C; Sun T; Wheeler DC; Yavin Y; Zhang H; Zinman B; Rosenthal N; Brenner BM; Perkovic V
    Circulation; 2019 Aug; 140(9):739-750. PubMed ID: 31291786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model.
    Willis M; Nilsson A; Kellerborg K; Ball P; Roe R; Traina S; Beale R; Newell I
    Diabetes Ther; 2021 Jan; 12(1):313-328. PubMed ID: 33263893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.